Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To explore the safety and efficacy of edaravone dexborneol for patients of acute ischemic stroke received endovascular therapy in extended time windows.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Edaravone

Criteria

Inclusion Criteria:

1. 18 to 80 years of age;

2. Acute ischemic stroke with National Institute of Health Stroke Scale (NIHSS) ≥ 10 and Volume of infarction on DWI <31ml or with a NIHSS ≥20 and 31mlinfarction<51ml(DWI);

3. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation;

4. Endovascular Therapy in 6-24 hours of stroke onset;

5. The availability of informed consent.

Exclusion Criteria:

1. First ever stroke or mRS≤1 after previous disease;

2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;

3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia

4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;

5. Severe cardiac or pulmonary disease;

6. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months;

7. Pregnancy, plan to get pregnant or during lactation;

8. Patients with contraindication or allergic to any ingredient of drugs in our study;

9. Unsuitable for this clinical studies assessed by researcher